Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 208

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A metaanalysis of 18F‐2‐deoxy‐2‐fluoro‐D‐glucose positron emission tomography in the staging and restaging of patients with lymphoma

Isasi, Carmen R., Lu, Ping, Blaufox, M. Donald·2005·Cancer

Abstract

BACKGROUND: In recent years, the use of positron emission tomography (PET) has become widespread for the staging and follow‐up of several malignancies. In the current study, the authors conducted a metaanalysis of the published literature to evaluate the diagnostic performance of 18 F‐2‐deoxy‐2‐fluoro‐D‐glucose PET (FDG‐PET) in the staging of patients with lymphoma. METHODS: The authors conducted a systematic MEDLINE search of articles published between January 1995 and June 2004. Studies that evaluated FDG‐PET with a dedicated camera and that reported sufficient data to permit the calculation of sensitivity and specificity were included in the analysis. Two reviewers independently reviewed the eligibility of the studies and abstracted data (sample population; characteristics of FDG‐PET; and the number of true‐positive results, true‐negative results, false‐positive results, and false‐negative results). The authors estimated the pooled sensitivity, false‐positive rate, and maximum joint sensitivity and specificity. RESULTS: Twenty studies were eligible for the metaanalysis. Fourteen studies included patient‐based data, comprising a sample size of 854 subjects, and 7 studies included lesion‐based data, totaling 3658 lesions. Among those studies with patient‐based data, the median sensitivity was 90.3% and the median specificity was 91.1%. The pooled sensitivity was 90.9% (95% confidence interval [95% CI], 88.0–93.4) and the pooled false‐positive rate was 10.3% (95% CI, 7.4–13.8). The maximum joint sensitivity and specificity was 87.8% (95% CI, 85.0–90.7). The pooled sensitivity and false‐positive rate appeared to be higher in patients with Hodgkin disease compared with those with non‐Hodgkin lymphoma. CONCLUSIONS: The results of the current study indicate that FDG‐PET is a valuable tool for the staging and restaging of patients with lymphoma; showing a high positivity and specifity. Clinicians may consider adding FDG‐PET to the staging workup of patients with lymphoma. Cancer 2005. © 2005 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.21253

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 208

Metadata

Authors
Isasi, C. R., Lu, P., & Blaufox, M. D.
Venue
Cancer
Publisher
Wiley
Published
2005-07-26
Volume
104
Issue
5
Pages
1066-1074
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2049513060
Cited by
208
References
2
FWCI
10.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A metaanalysis of 18F‐2‐deoxy‐2‐fluoro‐D‐glucose positron emission tomography in the staging and restaging of patients with lymphoma. https://app.cochat.ai/papers/10.1002/cncr.21253
The paper
Isasi, C. R., Lu, P., & Blaufox, M. D. (2005). A metaanalysis of 18F‐2‐deoxy‐2‐fluoro‐D‐glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. https://doi.org/10.1002/cncr.21253

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.